Ovarian status in healthy postmenopausal women: Follow-up 12 months after transvaginal ultrasound

Menopause

Volumn 16, Issue 6, 2009, Pages 1149-1155

  Bell, Robin J ^a   Healy, David L ^b   Robertson, David M ^c   Jobling, Tom ^b   Oehler, Martin K ^b   Edwards, Andrew ^d   Shekleton, Paul ^d   Oldham, Jacqueline ^d   Piessens, Sofie ^d   Teoh, Mark ^d   Mamers, Pamela ^b   Taylor, Nancy ^b   Walker, Frances ^b  

^a MONASH UNIVERSITY   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d MONASH MEDICAL CENTRE   (Australia)

Author keywords

CA 125; Inhibin; Ovarian health; Transvaginal ultrasound

Indexed keywords

CA 125 ANTIGEN; INHIBIN;

ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT; COHORT ANALYSIS; COMMUNITY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE DURATION; FEMALE; FOLLOW UP; HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; OVARY; OVARY CANCER; OVARY DISEASE; POSTMENOPAUSE; PREVALENCE; SURGICAL TECHNIQUE; TRANSVAGINAL ECHOGRAPHY;

ADULT; AGED; AGED, 80 AND OVER; CA-125 ANTIGEN; COHORT STUDIES; FEMALE; HUMANS; INHIBINS; MIDDLE AGED; OVARIAN DISEASES; OVARIAN NEOPLASMS; OVARY; POSTMENOPAUSE; REPRODUCIBILITY OF RESULTS; TIME FACTORS;

EID: 73249143684     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e3181aa1c93     Document Type: Article

References (15)

1. American Cancer Society. Can ovarian cancer be found early? Available at: http://www.cancer.org/docroot/CRI/content/CRI-2-4-3X-Can-ovarian-cancer-be- found-early-33.asp?sitearea=. Accessed June 25, 2009.
2. Havrilesky LJ, Sanders GD, Kulasingam S, Myers ER. Reducing ovarian cancer mortality through, screening: is it possible, and can we afford it? Gynecol Oncol 2008;111:179-187.
3. 3. Visintin I, Feng Z, Longton G, et al. Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res 2008;14:1065-1072. (Pubitemid 351302552)
4. Visintin I, Feng Z, Longton G, et al. Diagnostic markers for early detection, of ovarian cancer correction. Clin Cancer Res 2008;14:5308.
5. Greene MH, Feng Z, Gail M. The importance of test positive predictive value in ovarian cancer screening. Clin Cancer Res 2008;14:OF1.
6. Coates RJ, Kolor K, Stewart SL, Richardson LC. Diagnostic markers for ovarian cancer screening: not ready for routine clinical use. Clin Cancer Res 2008;14:7575-7576.
7. Healy DL, Bell R, Robertson. DM, et al. Ovarian status in healthy postmenopausal women. Menopause 2008;15:1109-1114.
8. Lappohn RE, Burger HG, Bouma J, et al. Inhibin as a marker for granulosa cell tumours. N Engl J Med 1989;321:790-793.
9. 9. Healy DL, Burger HG, Mamers P, et al. Elevated serum inhibin concentrations in postmenopausal women with ovarian, tumours. N Engl J Med 1993;329:1539-1542. (Pubitemid 23332439)
10. 10. Robertson DM, Stephenson T, Pruysers C, et al. Characterisation of inhibin forms and their measurement by an inhibin subunit ELISA in serum from postmenopausal women with ovarian cancer. J Clin Endocrinol Metab 2002;87:816-824. (Pubitemid 34158258)
11. Robertson DM, Cahir N, Burger HG, et al. Combined inhibin and CA-125 assays in the detection of ovarian cancer. Clin Chem 1999;45:651-658.
12. Soules MR, Sherman S, Parrott E, et al. Stages of Reproductive Aging Workshop (STRAW). J Womens Health Gend Based Med 2001;10: 843-848.
13. 13. Buys SS, Partridge E, Greene MH, et al. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am J Obstet Gynecol 2005;193:1630-1639. (Pubitemid 41540458)
14. Menon U, Jacobs IJ. The current status of screening for ovarian cancer. In: Jacobs ISJ, Sheperd JH, Oram DH, et al, eds. Ovarian Cancer. New York: Oxford University Press, 2002:171-178.
15. Johnson CC, Kessel B, Riley TL, et al. The epidemiology of CA-125 in women without evidence of ovarian cancer in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial. Gynecol Oncol 2008;110:383-389.